Skip to main content
. 2022 Jun 9;14(12):2408. doi: 10.3390/nu14122408

Table 1.

Baseline characteristics and endpoints of the study population, overall and by APOE-ε4 carriership.

Variable All Population
(n = 1490)
APOE-ε4 Non-carrier
(n = 1155) 1
APOE-ε4 Carrier
(n = 335) 2
ε3/ε4 + ε4/ε4
(n = 311)
Women—No. (%) 798 (53.6) 620 (53.7) 178 (53.1) 167 (53.7)
Age—Mean (SD) 73.0 (5.7) 73.2 (5.8) 72.4 (5.5) 3 72.5 (5.5)
Education—No. (%)
 No high school degree 64 (4.3) 49 (4.2) 15 (4.5) 15 (4.5)
 High school degree 341 (22.9) 275 (23.8) 66 (19.7) 62 (20.0)
 Some years of college 366 (24.6) 282 (24.4) 84 (25.1) 77 (24.8)
 College degree 505 (33.9) 384 (33.2) 121 (36.1) 112 (36.0)
 Unknown 214 (14.4) 165 (14.6) 49 (14.6) 45 (14.5)
Diabetes—No. (%) 256 (17.2) 202 (17.5) 54 (16.1) 53 (17.0)
Prevalent cardiovascular disease—No. (%) 330 (22.1) 252 (21.8) 78 (23.3) 74 (23.8)
RBC DHA, proportion of total fatty acids—Mean (SD) 5.00 (1.37) 5.00 (1.37) 5.00 (1.39) 5.04 (1.40)
Incident Alzheimer’s disease—No. (%) 131 (8.8) 77 (6.7) 54 (16.1) 3 51 (16.4) 3
Incident all-cause dementia—No. (%) 168 (11.3) 103 (8.9) 65 (19.4) 3 61 (19.6) 3

1 Includes ε2/ε2 (n = 7), ε2/ε3 (n = 191), and ε3/ε3 (n = 957). 2 Includes ε2/ε4 (n = 24), ε3/ε4 (n = 286), and ε4/ε4 (n = 25). 3 p < 0.05 vs. non-carrier. DHA, docosahexaenoic acid; RBC, red blood cell.